PubMed Health⌕ Search

Biomedical subjects

C Leleu

Publications and source records attributed to C Leleu.

14 recordsLinked to original sources
PubMed1990

Immunohistochemical markers defined by monoclonal antibodies and response to bacillus Calmette-Guérin endovesical immunotherapy for superficial bladder tumors.

As bacillus Calmette-Guérin (BCG) immunotherapy is highly effective for most but not all superficial bladder tumors, there is a need to define predictors of response to this mode of treatment. We have investigated a panel of markers defined by monoclonal antibodies, directed against tumor-associated transitional cell carcinoma antigen (G4 and E7), epidermal growth factor receptor, cytokeratin (CK) 18 and blood group antigens A, B and H, using an indirect immunoperoxidase staining on paraffin sections. Twenty superficial bladder tumors (T1) treated with intravesical BCG therapy (10 responders and 10 nonresponders) were tested with this panel. Among the responders, expression of CK18 antigen was positive in 7 and negative in 3, whereas in the nonresponder group it was positive in 2 and negative in 8. The difference was statistically significant (p less than 0.05). Loss of expression of CK18 antigenicity was associated with recurrence or progression of superficial bladder tumors following BCG therapy, indicating that changes in CK patterns should be investigated as potential predictive markers for response to BCG.

Administration, Intravesical↗
PubMed1989

Systemic bacillus Calmette-Guérin infection, 'BCGitis', in patients treated by intravesical bacillus Calmette-Guérin therapy for bladder cancer.

Among 169 patients treated for supeficial bladder tumor with 150 mg Pasteur-strain bacillus Calmette-Guérin (BCG) intravesical instillation, 5 cases of 'BCGitis' were observed, i.e. a severe systemic BCG infection with bronchopulmonary lesions and granulomatous hepatitis. In 4 cases, the complications appeared at the early stage of treatment (after the 3rd, 6th, 6th and 8th instillations, respectively). In 1 case, treated with monthly maintenance therapy for 2 years, BCGitis appeared 6 months after treatment had been completed and, in addition to pulmonary basal infiltrate and granulomatous hepatitis, intramedullary granulomatosis was observed. In 3 patients, trauma must be taken into consideration as BCGitis appeared after traumatic instillation with bleeding. All patients were cured by treatment with rifampicin, isoniazid and prednisone.

Administration, Intravesical↗
PubMed1989

Bladder tumors invading the lamina propria (stage A/T1): influence of endovesical bacillus Calmette-Guérin therapy on recurrence and progression.

47 patients with transitional cell bladder carcinoma invading the lamina propria (stage A/T1) were treated from 1984 to 1986 by complete transurethral resection followed by 1-3 cycles of endovesical bacillus Calmette-Guérin instillations, and followed 14-64 months by cytology, endoscopy and bladder biopsies, 64% achieved a complete response, 36% recurred (recurrence rate/100 months/patient 2.2), 21% progressed to muscle invasion. Duration of treatment, tumor size or type (solid vs. papillary), presence of carcinoma in situ bore no relation to the final result. The preceding history of T1 bladder tumor appeared associated with a higher risk of progression although not reaching statistical significance. The results were compared to those obtained by transurethral resection in a similar group of 50 patients treated from 1982 to 1984 and followed up 12-100 months, 90% recurred and 34% progressed to muscle invasion with a recurrence rate/100 months/patient of 9.22. Keeping in mind the limits of a nonrandomized historical comparison, it appears that endovesical bacillus Calmette-Guérin therapy alters favorably the recurrence pattern of T1 bladder cancer.

Adult↗
PubMed1989

Systemic bacillus Calmette-Guerin infection in patients treated by intravesical BCG therapy for superficial bladder cancer.

Among 169 patients treated for superficial bladder tumors with intravesical instillations of 150 mg BCG-Pasteur, five developed BCG-itis--a severe systemic infection with bronchopulmonary lesions and granulomatous hepatitis. In four cases, the complication appeared early during treatment (after three, six, six and eight instillations respectively). In one case, BCG-itis appeared 6 months after completion of 2 years monthly maintenance therapy. In addition to pulmonary basal infiltration and granulomatous hepatitis, intramedullary granulomatosis was observed. In three patients, the role of trauma has to be considered, as BCG-itis appeared after a traumatic instillation with bleeding. All patients were cured by combined treatment with Rifampicin, Isoniazid and Prednisolone.

Administration, Intravesical↗
PubMed1989

Bladder tumors invading the lamina propria (stage T1): influence of endovesical BCG therapy on recurrence and progression.

We treated 47 patients with transitional cell bladder carcinoma invading the lamina propria (stage T1) from 1984 to 1986 with complete transurethral resection followed by one to three courses of endovesical BCG instillation and followed them for 14-64 months with cystoscopic and endoscopic tests and bladder biopsy. Complete response was achieved in 64%, and 36% had recurrences (recurrence rate per 100 month/patient, 2.2); 21% progressed to muscle invasion. Duration of treatment, tumor size or type (solid versus papillary), and presence of carcinoma in situ bore no relation to the final result. A history of previous T1 bladder tumor appeared associated with a higher risk of progression, although not statistically significantly. The results were compared with those obtained by transurethral resection alone in a similar group of 50 patients treated from 1982 to 1984 and followed for 12 to 100 months. Of these 90%, had recurrence, and 34% progressed to muscle invasion, with a recurrence rate per 100 month/patient of, 9.2. In light of the limits of a non-randomized historical comparison, it appears that endovesical BCG therapy favorably alters the recurrence pattern of T1 bladder cancer.

Administration, Intravesical↗
PubMed1988

[Wilson's disease with liver copper in normal concentration].

The cases of 2 children with Wilson's disease revealed by persistent hypertransaminasemia are reported. Blood ceruloplasmin concentration was low but the liver content of copper was lower than usually seen in presymptomatic forms of the disease. The apparently low liver copper concentration could be explained by an unusually important steatosis.

Child↗
PubMed1988

[Continent replacement enterocystoplasty using a low-pressure detubularized ileal pouch after radical prostatocystectomy].

Tubular ileal-ileo-caecal or colonic replacement enterocystoplasties induce nocturnal incontinence in more than 70% of cases, partly due to the presence of peristaltic waves responsible for pressures greater than 40 cm of water for low filling volumes. The use of debutularised intestinal grafts considerably attenuates these pressure waves, ensuring excellent diurnal continence and a dramatic reduction in nocturnal incontinence together with protection of the upper urinary tract. The detubularised ileal bladder combines the reliability of all low pressure reservoirs with a simple technique: a 30 cm ileal segment is isolated then opened 2 cm from its anti-mesenteric border. The two limbs of the loop are sutured to each other. The ureters are reimplanted at the summit of each limb according to the mucosal groove procedure and the summit of the pouch is anastomosed to the urethra. This procedure has been used in 10 patients following radical cystectomy for cancer. Seven of these patients underwent clinical, radiological and urodynamic examination 5 months after the operation: all 7 patients were continent during the day. Nocturnal continence was obtained at the cost of getting up one or twice during the night, but incontinence persisted in the other 3 patients. Cystometry did not reveal any pressure waves greater than 25 cm of water for a volume of 500 ml. The detubularised ileal bladder is simple to perform and constitutes a reasonable alternative to traditional tubular enterocystoplasties.(ABSTRACT TRUNCATED AT 250 WORDS)

Aged↗
PubMed1986

[Treatment of superficial tumors and carcinomas in situ of the bladder by intravesical BCG therapy].

89 patients with a superficial tumor of the bladder were treated with intravesical BCG: 150 mg of the Pasteur strain was instilled once a week for 6 weeks, once every other week for 3 months and once a month for 2 years, in 4 groups of patients. Group I: 20 patients with primary carcinoma in situ (CIS); 18 have been monitored for more than 6 months: in each, cytology has become negative; 16 were controlled by TUR: in all but one complete regression of CIS was observed. Group II: 24 patients with stage O tumor; in 16, follow up is greater than 12 months : the recurrence rate dropped from 11.12/100 months patients to 1.52/100 months patients. Group III: 12 patients with stage A tumor: in 10, follow up is greater than 12 months; 2 patients had tumor recurrence. Group IV: 28 patients with stage O or stage A tumor associated with CIS; in 17, followup is greater than 12 months: CIS disappeared in 13, but in 2 recurrences were observed (stage O without CIS). In addition to irritative side effects on the bladder, we observed complications in four cases: epididymitis in 2 patients and BCG spread with granulomatous hepatitis and bronchopulmonary lesions in two others.

Administration, Topical↗
PubMed1984

[Malakoplakia].

Malakoplakia is a fairly rare disease, normally found in women (four out of every five cases). It mainly attacks the urinary system, but may spread to the other viscera. The symptoms are not clinically specific. The main interest of the disease is its pathogenesis, from which its treatment is derived. It is in fact an immunological dysfunction of the phagocytes, leading to chemical disorders in the macrophages. Its treatment is based on the use of cholinergic agonists and vitamin C therapy.

Female↗